









This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ejh.12819 
This article is protected by copyright. All rights reserved. 
Received Date : 30-May-2016 
Revised Date   : 16-Aug-2016 
Accepted Date : 07-Oct-2016 
Article type      : Original Article 
 
 
Article Title: Novel G6B gene variant cause familial autosomal recessive 
thrombocytopenia and anemia  
Running title: Melhem et al. G6B NOVEL VARIANT CAUSE THROMBOCYTOPENIA 
AND ANEMIA 
Motasem Melhem1*, Mohamed Abu-Farha2*, Dinu Antony1*, Ashraf Al Madhoun1*, 
Chiara Bacchelli3, Fadi Alkayal4, Irina AlKhairi2, Sumi John5, Mohamad Alomari6, Phillip 
L Beales3, and Osama Alsmadi1 
* Contributed equally 
1Genetics and Genomics Department, Dasman Diabetes Institute, Kuwait; 2Biochemistry 
and Molecular Biology Department, Dasman Diabetes Institute, Kuwait; 3Genetics and 
Genomic Medicine, UCL Institute of Child Health, London, UK; 4Pancreatic islet Biology 
& transplantation Unit, Dasman Diabetes Institute, Kuwait; 5Integrative Informatics, 
Dasman Diabetes Institute, Kuwait; 6Department of Pathology, Windsor Regional 
Hospital, Canada. 
Corresponding author: Dr. Osama Alsmadi, Genetics and Genomics Unit, Dasman, Diabetes 
Institute, P.O. Box 1180, Dasman15462, Kuwait. 
Tel: Phone: +965 2224 2999 Ext. 4343, Fax: + 965 2249 2406. 
Email: osama.alsmadi@dasmaninstitute.org  
 










This article is protected by copyright. All rights reserved. 
Abstract 
Objective: To characterize the underlying genetic and molecular defects in a 
consanguineous family with life-long blood disorder manifested with thrombocytopenia 
(low platelets count) and anemia. 
Methods: Genetic linkage analysis, exome sequencing and functional genomics were 
carried out to identify and characterize the defective gene. 
Results: We identification of a novel truncation mutation (p.C108*) in Chromosome 6 
Open Reading Frame 25 (C6orf25) gene in this family. We also showed the p.C108* 
mutation, was responsible for destabilizing the encoded truncated G6B protein.  Unlike 
the truncated form, wild-type G6B expression resulted in enhanced K562 differentiation 
into megakaryocytes and erythrocytes.  C6orf25, also known as G6B, is an effector 
protein for the key hematopoiesis regulators, Src homology region 2 domain-containing 
phosphatases SHP-1 and SHP-2. 
Conclusion: G6B seems to act through an autosomal recessive mode of disease 
transmission in this family, and regarded as the gene responsible for the observed 
hematological disorder. This inference is well supported further by in vivo evidence 
where similar outcomes were reported from G6b-/- and SHP1/2 DKO mouse models. 
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Introduction 
Blood disorders can result from developmental molecular impairments in the bone 
marrow progenitor cells as a result of abnormal cellular division and/or differentiation. 
Thrombocytopenia and anemia are two distinctive examples of these blood anomalies. 
Thrombocytopenia is characterized by low platelets counts that are below normal levels 
(˂50,000/μl) compared to healthy individuals, whereas anemia is caused by a reduction 
in hemoglobin contents and/or low red blood cell (RBC) counts [1-5]. Platelets-
producing megakaryocytes (MEGs) and RBCs derive from a common ancestor 
progenitor cells in a process that is regulated by several transcription factors including 
GATA binding protein 1 (GATA1) [6]. Genetic defects in GATA1 gene can lead to 
anemia and/or thrombocytopenia [7]. Defects in other transcription factors such as T-
cell acute lymphoblastic leukemia 1 (TAL1), FOG family member 1 (FOG1), and nuclear 
factor erythroid 2 (NFE2), can also lead to erythroid and megakaryocytic alteration, 
which manifest in anemia and low platelets count, respectively [8]. Other factors can 
alter the generation of one lineage over the other; for example FLI1 proto oncogene 
(FLI1) prompts MEGs production, whereas Kruppel-like factor 1 (KLF1) prompts RBCs 
formation [9, 10]. Heritable thrombocytopenia may be transmitted as autosomal 
dominant, recessive, or X-linked [11]. Certain forms of anemia including thalassemia, 
sickle cell and Fanconi anemia are also heritable [12, 13]. Thalassemia and sickle cell 
anemia constitute the majority of inherited recessive hemoglobin disorders worldwide 
[14]. In the Arabs world, hemoglobinopathies are mainly sickle cell anemia and β-
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available on the incidence of heritable thrombocytopenia among Arab population at the 
current time. 
High consanguinity rates combined with large family size are associated with increased 
incidence of rare and heritable disorders, with the autosomal recessive forms 
dominating the transmission of such disorders.  A study in 2010 reported  10.4 % of the 
overall world marriages are consanguineous [16].  Marriage  between relatives is 
commonly practiced in the Middle East, exceeding 50% of all marriages for some 
countries [17].  For some Mediterranean Arab families, this inbreeding practice often 
unites double first cousins with breading co-efficient (F) of 0.125, and that naturally 
manifests with increased risk of autosomal recessive disorders [18]; this increase is a 
direct result from the enrichment of regions of homozygosity (ROH) that are embracing 
deleterious gene variants. 
Using homozygosity mapping and whole exome sequencing, we report the discovery of 
a defective G6B recessive novel gene in multiply affected siblings from a 
consanguineous Arab family. All affected members are significantly exhibiting life-long 
reduced platelets counts combined with anemia phenotype. We show that a truncation 
mutation in G6B was responsible for this phenotype, as evidenced by the wild-type G6B 
expression which enhanced K562 cells differentiation into megakaryocytes and 
erythrocytes; the truncated form of G6B failed to enhance this differentiation.  The 
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Methods: 
Enrollment of Study Participants 
Study participants are all adults above the age 21 years, and belong to a 
consanguineous family of an Arabian origin. All participants agreed and voluntarily 
joined this study. Clinical history was taken for all members by their family doctor, 
followed by withdrawal of 8ml of blood into two EDTA anti-coagulated tubes for plasma, 
RNA and DNA extractions. 
 
Linkage Analysis 
High density genotyping approach was performed to identify the locus harboring the 
disease gene, using Illumina Human OmniExpress bead genotyping array (Illumina Inc.; 
San Diego, CA, USA; n=730,525 SNP markers). Genotyping was carried out in Dasman 
Diabetes Institute genome centre, Kuwait. Call rate of 99.9% was used for concordance 
and quality control (QC) checks, using Illumina GenomeStudio software. Linkage 
analysis assumed an autosomal recessive model of disease transmission, with 100% 
penetrance in this consanguineous family. Family based association test (FBAT) using 
Golden Helix software was utilized for the analysis [19]. The critical locus from the FBAT 
analysis, was used to guide the shortlisting of candidate genes in the second tier 
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Whole Exome Sequencing 
For Whole Exome sequencing was carried out according to Illumina TrueSeq 
Enrichment standardized protocol. Detailed filter settings are given in supplementary 
Tables 1 & 2.  
 
G6B Plasmids Transient Transfection using K562 Cells 
Human myelogenous leukemia cell line (K562) was obtained from American Type 
Culture Collection (Rockville, Baltimore, MD). Cells were cultured in suspension using 
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine 
serum and penicillin/streptomycin. Both wild-type (full length) and the truncated forms of 
G6B were cloned into pCMV-6 vector with either FLAG or GFP tags at the c-terminus. 
For transient transfection assays, 10X106 K562 cells were used and were transfected 
with either mock, wild-type  or truncated G6B. Both FLAG and GFP tagged clones were 
used. Briefly, 24 μg of plasmid DNA were mixed with Lipofectamine 3000 as 
recommended by the manufacturer (Invitrogen, Carlsbad, CA) and added to the cells in 
antibiotics free media. Media was changed after 24 hours of transfection and the cells 
were grown in complete EMEM media for another 24-hours before harvesting for protein 
analysis. 
 
Platelet- versus Erythrocyte-like differentiation of K562 cells 
Transiently transfected K562 cells, with the described G6B constructs, were 
differentiated into platelet-like and erythrocyte-like cells using phorbol 12-myristate13-
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21] with minor modifications. For platelet-like differentiation, K562 (5x105 cells) were 
transiently transfected with wild type G6B, truncated G6B or empty vector and then 
were differentiated a RPMI media containing 10% FCS,  1% Pen/Strep, and 16 nM 
PMA. The differentiation media was changed daily for a period of 6 days. Similarly, for 
erythrocyte-like generation, the transfected K562 cells were treated a differentiation 
media containing with 0.6 nM Na-Bu instead of PMA. Cells were harvested at a time 
course intervals (6 hrs, days 2, 4, and 6) for mRNA extractions. All differentiation 
experiments were performed in triplicates. K562 transiently transfected and 
differentiated in three independent experiments. The transfection efficiencies where 
normalized to reduce variations within each experiment. Statistical significance was 
estimated with a one-tailed Student’s t-test assuming equal variance and error is s.e.m.  
(*P < 0.05). 
 
Results 
Clinical Summary and Microscopic Findings 
A consanguineous Arabian family (Figure 1) with nine siblings (two daughters and 
seven brothers) was investigated in this study. Four of the siblings (II, IV, V and VII) 
manifested at early childhood with persisting thrombocytopenia and anemia. The 
parents are first cousins, with no history of hematological abnormalities. Ages of siblings 
from oldest (I) to youngest (IX) are 50, 48, 45, 42, 41, 38, 33, 30 and 28 years, 
respectively.  Interestingly, siblings II and V developed a significant splenomegaly and 
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Hemoglobin levels of the affected participants varied throughout their life ranging 
between 6 and 10 gm/dl. Variable thrombocytopenia was also observed in the affected 
siblings with platelets counts ranging from 10,000-40,000/μl.  Apart from bruising, there 
is no history of major bleeding. White blood cells counts were always normal for all 
siblings whether affected of not. No history of increased infections or signs of decreased 
immunity either was reported. 
The peripheral blood smears of those affected showed normal white blood cells 
morphology, and confirmed the severe thrombocytopenia compared to the normal 
siblings. The morphology of platelets was within normal except for increased numbers 
of giant platelets.  The red blood cells showed moderate anisopoikilocytosis with tear 
drop shape.  Rare nucleated red blood cells and neutrophil precursors (e.g. myelocytes 
and metamyelocytes) could also be identified (leukoerthroblastic reaction).   
Each affected sibling had multiple bone marrows biopsies, done over their life course, 
with all these showing a dry tap.  The biopsies smears were normo-cellular to hyper-
cellular with all three hematopoietic cell lines being well represented.  Megakaryocytes 
were increased in number with focal clustering.  Some enlarged megakaryocytes were 
also identified.  A moderate to severe reticulin fibrosis was also present.  No increase in 
CD34+ blasts could be demonstrated. The bone marrows and peripheral blood smears 
were evaluated by independent hematopatholgists, and all determined the phenotype is 
consistent with myeloproliferative disorder in this family, with features most compatible 
with myelofibrosis.  
Cytogenetic studies showed normal karyotypes. No karyotyping was performed on the 
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iron and B12/folic acid supplements.  Occasional transfusions were given when needed. 
Treatment with steroids was attempted with the two siblings showing splenomegaly and 
lower hemoglobin levels, however this had not led to any improvements. 
 
Linkage Analysis and Exomes Sequencing 
Results revealed an FBAT log-10 score = 1.94, with the critical interval minimized to 
27.7Mb DNA stretch on the petite “P” short arm of chromosome 6, between SNPs 
rs13195345 & rs1537638, which encompass a region between p22.3 and p21.1 
cytogenetic bands. There were more than 500 genes present in this locus, many of 
which classified amongst HLA or the autoimmune gene families. 
Since members of both gender were affected and parents had normal platelet and RBC 
levels an autosomal recessive mode of inheritance was assumed for analysis. The filter 
cascade used for ingenuity analysis is shown in supplementary Table 1. The quality of 
the sequence reads were assessed using Integrative Genomics Viewer Software (IGV; 
Broad Institute, MA, United States). 
Analysis was carried out on exomes from one affected male and his affected sister (II & 
V respectively), in addition to an unaffected male (III) from this family were sequenced, 
along with 40 exomes from our in-house database of normal unaffected controls. 
Ingenuity variant analysis software was used for this analysis (see supplementary tables 
1 and 2 for analysis parameters details). List of deleterious variants identified within the 
critical linkage interval between the SNPs rs13195345 & rs1537638 were catalogued 
(Supplementary Table 3). A total of 2571 genomic deleterious variants were detected in 
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and only C6orf25 (c.324C>A; p.C108*) was seen in a homozygous state in the two 
affected siblings. This change was not seen in the unaffected sibling (III) from this 
family, or in any of the 40 in-house controls.  p.C108* according to ingenuity analysis, 
showed an association value of p=4.71E-07, and an odds ratio of 1485, further 
confirming the pathogenic effect predicted from this gene alteration. 
The identified C6orf25 variant (c.324C>A) was assessed further for its clustering 
(segregation) by examining its genotypes via Sanger sequencing in all eight 
participating family members (The genotypes were confirmed as homozygous only in 
the affected siblings, whereas this variant was heterozygous in the mother (father 
deceased) and unaffected siblings (see figure 1), which is consistent with a classical 
autosomal Mendelian disease transmission pattern in this consanguineous family. 
Sanger sequencing also confirmed c.324C>A variant was absent when examined in 
another 94 DNA controls from ethnically-matched unrelated healthy controls, again 
confirming this variant is novel and deleterious. Furthermore, this rare variant was also 
absent from the global variant databases including dbSNP, 1000 genome project, 
NHLBI exome sequencing project and ExAC. A representative chromatogram showing 
the mutation and genotypes in the family is shown in Figure 2. c.324C>A corresponds to 
a truncation nonsense mutation substituting the cysteine codon at position 108 in the 
encoded peptide with the stop codon TGA (p.C108*). This mutation eliminates the 
transmembrane domain, in addition to the cytoplasmic domain which encompasses the 
immunoreceptor tyrosine-based inhibition motif (ITIM) with its two tyrosine residues 
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C6orf25 gene, also known as G6B (Ensembl ID: ENSG00000204420), is located in the 
major histocompatibility complex (MHC) class III region on chromosome 6, and a 
member of the immunoglobulin (Ig) superfamily.  The protein encoded by this gene is a 
glycosylated cell surface receptor that is bound to the plasma membrane, however 
different transcript variants of this gene also encode soluble protein isoforms that can be 
found in the endoplasmic reticulum and Golgi that can be detected in the blood 
circulation [22, 23]. 
 
G6B enhances hematopoietic lineage differentiation 
The role of wild type and truncated G6B in the enhancement of megakaryocytes, 
platelet precursors, or erythrocytes differentiation was evaluated using the human 
chronic myelogenous leukemia cell line K562, in the presence of PMA or Na-Bu, 
respectively. At day 6 of K562 differentiation, qrtPCR analyses demonstrated 33- and 
320-fold induction of the platelet unique markers CD41 and CD61, respectively, relative 
to the undifferentiated cells that are transiently transfected with the scrambled (mock) 
control plasmid; suggesting PMA is sufficient to induce megakaryocyte/platelet 
differentiation (Figure 3A) [24, 25] . Interestingly, K562 PMA treated cells transfected 
with wild-type G6B showed a significant stimulation of platelets differentiation. In these 
cells, the transcription of CD41 and CD61 was 33- and 22.5- folds higher than that of 
cells transfected with the scrambled (mock) plasmid construct. Further, in these cells, 
the expression of CD41 and CD61 was highly significant at day 4; implying that G6B 
enhances early induction of platelets lineage. On the other hand, cells transfected with 
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and 2-fold, respectively), similar to that seen with the scrambled plasmid transfections, 
suggesting a residual possible functional role for the endogenous G6B in these cells 
(Figure 3A). 
Transfections of K562 cells treated with Na-Bu resulted in distinctive differential 
expression of markers specific to the erythropoetic lineage. At day 6 and under similar 
differentiation conditions, the scrambled plasmid-transfected K562 cells showed 
temperate expressions of erythrocyte markers CD44 and KLF1, with 15- and 6-folds 
relative to baseline expression at day 0, respectively (Figure 3B), consistent with a 
previous report [21]. The same trend and magnitude was also observed in cells 
expressing the truncated G6B (Figure 3B). The wild-type G6B transfection, particularly 
enhanced the erythrocytic genes expression with a substantial relative induction starting 
at day 4. At day 6, both CD44 and KLF1 relative expression, compared to that of the 
scramble vector was 11.6- and 8.5-folds higher, respectively, and statistically significant 
(Figure 3B).  
Taking together, these results revealed a potential role for G6B in enhancing the 
differentiation of K562 cells into platelets or erythrocytes, in the presence of PMA or Na-
Bu, respectively. Nevertheless, G6B alone was not sufficient to induce the 
hematopoietic lineages (data not shown). 
 
Truncated G6B Leads to Degradation 
In order to study the effect of the truncation on the mutant G6B protein, both wild-type 
and truncated forms of the protein were expressed in K562 cells using FLAG-tag pCMV-
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antibodies showed wild-type G6B protein is detectable while the truncated form was 
absent, suggesting its degradation (Figure 4A). Quantitative rtPCR RNA analysis of 
confirmed transfection by both constructs was equally efficient as shown in Figure 4B. 
Both wild-type and truncated forms of G6B showed over 800 fold increase in expression 
compared to the mock control. 
 
Proteasome Inhibitor and GFP Tagging Stabilize the Truncated G6B Protein  
To test whether G6B protein is degraded by the proteasome or lysosome mechanism, 
cells expressing either wild-type or truncated G6B were treated with proteasome 
inhibitor (MG132, 10μM) and lysosome inhibitor (chloroquine, 100μM), respectively. 
Treatment with the proteasome inhibitor did not affect the wild-type, but caused mild 
stabilization of the truncated form Figure 4C. Treatment with the lysosome inhibitor did 
not affect the wild-type G6B protein expression and did not cause any stabilization to 
the truncated form Figure 4E. G6B gene expression for both treatments was similar and 
was not affected by either treatment Figure 4D, F.  
GFP tagged G6B protein was also used to rule out the impact of the tag on the 
expression of the G6B protein. To our surprise, GFP tagging of the truncated G6B 
protein had led to stabilization of the truncated form as shown in Figure 5A. Treating 
with the proteasome or the lysosome inhibitors did not affect the protein stability for 
either form as shown in Figure 5C, E. G6B gene expression was similar between 
truncated and wild-type G6B and was not affected by the proteasome or the lysosome 
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Predicted G6B protein Structure 
Using the SWISS-MODEL Workspace [26], we predicted the protein structure of the 
wild-type  and truncated forms of G6B. As shown in Figure 6A, the predicted wild-type 
G6B protein structure contains a number of beta-sheets that forms an organized tertiary 
structure. The truncated form of G6B is missing the beta-sheets structure present in the 
wild-type. On the other hand, tagging of the truncated G6B protein with GFP has 
caused major changes in its structure that has possibly lead to its stabilization as shown 
in Figure 6 C- D. 
 
Discussion 
Using linkage analysis and exome sequencing on a consanguineous family with 
unusual blood disorders manifested with thrombocytopenia and anemia, we have 
identified a defective novel G6B gene which maps to short arm of chromosome 6 (band 
6p21.3). G6B, also known as C6orf25, which localizes to MHCIII locus, between MHC 
classes I & II [23], is not a well characterized gene. We have identified a homozygous 
mutation (c.324C>A) in the G6B gene, only in the affected members of this family, 
suggesting cosegregation of homozygous c.324C>A with the disease is strong proof 
that this mutation is causal. 
What we know on G6B role in human is primarily its inhibition of platelets aggregation 
through the interaction with SHP-1 and SHP-2 [27]. Recent mouse knock out data also 
suggested G6B signals through, and plays as major regulator of SHP-1 and SHP-2 [28, 
29] affecting megakaryocytic development, platelet production, and function. 
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had in addition to severely reduced platelets production, an additional hematologic 
aberrations, including a 26% reduction in red blood cells and a 4.2-fold increase in white 
blood cells, highlighting significant defects in hematopoiesis and immunity [28]. SHP1/2 
DKO was lethal in this mouse model as observed in the first few weeks of life. In case of 
our affected family members who are homozygous for the p.C108* mutation, we find it 
intriguing and question whether exists a redundant mechanism, that is G6B-
independent, compensating for their G6B loss of function. While Mazharian and 
colleagues [29] reported a reduced platelets count in G6b-B–deficient mice model, there 
was no information on erythrocytes production, and we are uncertain if such phenotype 
was documented in their studies. 
G6B encodes a putative cell surface immunoglobulin (Ig) superfamily membrane 
receptor with a transmembrane segment, and a cytoplasmic tyrosine-based inhibitory 
motif (ITIM) with two tyrosine residues [30]. ITIMs are known to interact with Src 
homolog 2 (SH2) domain-containing protein tyrosine phosphatases (PTPs) such as 
SHP-1 and SHP-2. Human SHP1 & SHP2 are encoded by PTPN6 and PTPN11 genes, 
respectively [31]. Upon activation of the membrane-bound G6B, SHP-1 and/or SHP-2 
are recruited to negatively regulate the activation signal via a dephosphorylation 
mechanism [30, 31]. 
The phosphorylation of G6B is also under the control of LYN, a member of the Src 
family kinases (SFKs). LYN is one of the eight kinases belonging to the SFKs family [32] 
with a known inhibitory role in the myeloid lineage proliferation, and is physically 
associated with membrane receptors who lack their own catalytic motifs, and hence act 
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signaling in B-cells. The activation of immunoglobulin receptors on these cells trigger 
their entry into G1 phase which is required in cells division [34]. Upon phosphorylation 
of tyrosine residues within the ITIM of receptor proteins by LYN (e.g. G6B), other 
kinases like spleen tyrosine kinase (SYK), phospholipase Cγ2 (PLCγ2) and 
phosphatidyl inositol-3 kinase (PI3K) are also recruited as part of the activation cascade 
[35, 36].  Only scarce human LYN data is available in current literature, and most of the 
knowledge on this kinase is derived from mice studies. LYN-deficient mice display a 
spectrum of phenotypes including splenomegaly, and several types of monocyte and 
macrophage tumors [32]; splenomegaly was one of the clinical complications that were 
reported in the family studied here, which is consistent with the mouse studies. LYN 
signaling cascade triggers downstream effects including cellular proliferation and 
differentiation into a myeloid precursor of megakaryocyte and erythroblast lineages 
which subsequently lead to the formation of platelets and erythrocytes, respectively [37]. 
 
Both megakaryocytes and erythrocytes are generated through a late differentiation 
event from a common precursor from hematopoietic progenitor cells (HPCs). Several 
transcription factors are shared in this differentiation pathway including GATA1, GATA2, 
NFE1, NFE2, and FOG1 [38]. We hypothesize that anemia and thrombocytopenia 
phenotypes observed in the affected members of this family, is a consequence of 
expressing a non-functional G6B protein, and further propose a pathological 
mechanisms that is independent from the above regulating genes. This is supported by 
our PMA- and Na-Bu- driven differentiation in presence of the wild-type or mutant G6B 
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cascade is interrupted in case of the affected family members, who likely expressing an 
unstable mutated G6B protein product instead of the native G6B protein; this 
speculation is suggested by the western analysis results shown in figure 4, however this 
needs an independent confirmation using platelets from the affected family members. 
Future investigations on G6B using cellular and mouse G6B KO biological systems will 
be essential to dissect this gene’s molecular mechanism in humans, and further 
delineate its exact role in anemia and thrombocytopenia pathogenesis. 
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Figure Legends 
 
Figure1. Family pedigree showing siblings and affection status. 
Square symbol represent males and circle symbol represent females. Filled symbols indicate positive 
affection status. 
 
Figure 2. Representative chromatograms showing the mutation and genotypes in all family 
members. 
Chromatogram of affected participants II, IV, V and VII 1 is showing homozygous AA genotype of variant 
c.324C>A located in the second coding exon, and results in a nonsense mutation (p.C108*). Mother and 
unaffected siblings have this change in heterozygous state. 
 
Figure 3.The functional role of G6B enhancing hematopoietic lineage differentiation of K562 cells 
in the presence of PMA or Na-Bu. 
Transiently transfected cells with wild type-G6B, truncated-G6B mutant or monk vector treated with (A) 
PMA to induce platelet generation or (B) Na-BU to induce erythrocytes differentiation showed significant 
enhancement of platelet- or erythrocyte- differentiation. In absence of inducing molecules, G6B failed to 
induce the hematopoietic lineages. RNA was collected at different time points, qrtPCR was performed 
and results were normalized against GAPDH and expressed as a fold-change relative to undifferentiated 
day 0 cells, (n=3, *p<0.05 relative to 6 hours incubation with the compound; **p<0.05 relative to day 6 
Flag transfected cells). 
 
Figure 4. Expression of FLAG tagged wild-type and mutant G6B. 
(A) Wild-type and truncated FLAG tagged forms of G6B transfected in K562 showing the degradation of 
the truncated form of G6B in untreated K562 cells. (C) Treating with proteasome inhibitor (MG132, 10μM) 
did not cause a major increase in protein stability and caused mild inhibition of the proteasome 
degradation (E) lysosome inhibitor (chloroquine, 100μM) did not lead to stabilization of the truncated G6B 
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mRNA level. No significant difference was observed at the mRNA level between wild-type and truncated 
G6B. Experiments were performed at n=3. 
 
Figure 5. Expression of GFP tagged wild-type and mutant G6B. 
(A) Wild-type  and truncated GFP forms of G6B transfected in K562 showing the stabilization of the 
truncated form of G6B in untreated K562 cells as well as cells treated with (C) proteasome inhibitor 
(MG132, 10μM) or (E) lysosome inhibitor (chloroquine, 100μM). Truncated form of G6B was stabilized by 
the GFP tagging under various treatments (B, D&F). Transfection efficiency of the wild-type and the 
truncated form of G6B is measured at the mRNA level. No significant difference was observed at the 
mRNA level between wild-type and truncated G6B. Experiments were performed at n=3. 
 
Figure 6.  SWISS-MODEL workspace predicted G6B protein structure. 
(A) wild-type and (B) truncated forms of G6B highlighting the disruption in the tertiary protein structure 
caused by the truncation. (C and D) SWISS-MODEL workspace predicted protein structure of GFP 
tagged wild-type and truncated G6B protein. 
 
Figure 7.  A schematic diagram depicting G6B signaling [pathway in wild-type and truncated G6B.  
In the presence of wild-type (A) compared to truncated (B) G6B, where SHP1/2 interactions with the 
mutated G6B is disrupted, leading to dysregulation of the downstream erythroid and megakaryocytic 
differentiation events. 
 
Supplementary Figure 1. A blood smear film image from an affected family member. 
Peripheral blood smear showing tear drop shaped red blood cell (black arrow).  A nucleated red blood cell 
(up arrow) and a metamyelocyte (down arrow) are also present compatible with leukoerythroblastic 
reaction; which is typically seen with myelofibrosis.  
